Crinetics Pharmaceuticals Inc (CRNX) - Total Assets
Based on the latest financial reports, Crinetics Pharmaceuticals Inc (CRNX) holds total assets worth $1.40 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Crinetics Pharmaceuticals Inc (CRNX) shareholders funds for net asset value and shareholders' equity analysis.
Crinetics Pharmaceuticals Inc - Total Assets Trend (2016–2025)
This chart illustrates how Crinetics Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Crinetics Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Crinetics Pharmaceuticals Inc's total assets of $1.40 Billion consist of 92.3% current assets and 7.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.9% |
| Accounts Receivable | $592.00K | 0.1% |
| Inventory | $2.02 Million | 0.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Crinetics Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Crinetics Pharmaceuticals Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Crinetics Pharmaceuticals Inc's current assets represent 92.3% of total assets in 2025, a decrease from 98.1% in 2016.
- Cash Position: Cash and equivalents constituted 8.9% of total assets in 2025, down from 96.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 0.2% of total assets.
Crinetics Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Crinetics Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180
|
China | CN¥11.69 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
USA | $319.43 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Crinetics Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.60 | 22.53 | 17.73 |
| Quick Ratio | 18.56 | 22.53 | 17.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.25 Billion | $1.23 Billion | $199.44 Million |
Crinetics Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Crinetics Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.09 |
| Latest Market Cap to Assets Ratio | 3.42 |
| Asset Growth Rate (YoY) | -20.8% |
| Total Assets | $1.14 Billion |
| Market Capitalization | $3.88 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Crinetics Pharmaceuticals Inc's assets at a significant premium (3.42x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Crinetics Pharmaceuticals Inc's assets decreased by 20.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Crinetics Pharmaceuticals Inc (2016–2025)
The table below shows the annual total assets of Crinetics Pharmaceuticals Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.14 Billion | -20.85% |
| 2024-12-31 | $1.43 Billion | +125.79% |
| 2023-12-31 | $635.35 Million | +80.41% |
| 2022-12-31 | $352.18 Million | +0.33% |
| 2021-12-31 | $351.01 Million | +91.35% |
| 2020-12-31 | $183.44 Million | +40.70% |
| 2019-12-31 | $130.38 Million | -23.94% |
| 2018-12-31 | $171.41 Million | +998.95% |
| 2017-12-31 | $15.60 Million | +23.80% |
| 2016-12-31 | $12.60 Million | -- |
About Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acrome… Read more